Victor Kravchenko*, Oleg Rakov, Olena Kovzun, Andriy Kovalenko and Viktoria Rakova

SI "VP Komissarenko State Institute of Endocrinology and Metabolism National Academy of Medical Sciences of Ukraine”, Ukraine

*Corresponding Author: Victor Kravchenko, Department of Epidemiology Endocrine Diseases, SI "VP Komissarenko State Institute of Endocrinology and Metabolism National Academy of Medical Sciences of Ukraine”, Ukraine.

Received: June 03, 2021; Published: July 29, 2021

Abstract

Vitamin due to the presence of the receptor (VDR), which is found in almost all nuclear cells is an important regulator in the pathogenesis of many diseases. The question of the causal relationship between vitamin D deficiency and Graves 'disease and the importance of this vitamin for thyroid function in the treatment of Graves' disease deserves special attention. The aim of the study was to investigate the level of 25- (OH) D in the body in Graves' disease and its relationship with thyroid function. We examined 143 patients who were first diagnosed with moderate Graves' disease (GD). All patients studied by us, residents of Ukraine, 67% of them live in Kyiv, 19% in Kyiv region, 14% in other regions of Ukraine. The average age of the subjects was 43.8 ± 0.95, among whom were men 22.4%, women - 77.6%. The analysis of immune parameters and thyroid function depending on the age of patients, the content of vitamin D in the serum, and its quartile distribution before treatment. Subsequently, all patients were divided into two groups depending on the therapy. The first group included 73 subjects, whose average age was 44.69 ± 1.39, patients in this group received tyrosol at a dose of 5 - 10 mg per day. The second group consisted of 70 patients. whose average age was 42.93 ± 1.29, they took tyrosol at a dose of 5-10 mg per day and vitamin D preparations - 2000 MO/day. In patients with Graves' disease. the highest content of 25- (OH) D in serum was observed in the age group of 19-30 years -59.1 nmol/l and a low level of antibodies to the TSH receptor - 9.0 mUi/l. A significant decrease in the immune index was observed only in the 3^rd and 4^th quartiles, when the content of 25- (OH) D in the serum reached 47.5 nmol/l and above, i.e. approached a moderate deficit. At a slight increase to 34 nmol/l, such changes were insignificant. After 3 months of treatment, the level of AbrTSH in the serum during treatment with vitamin D was twice lower than when treated with tyrosol alone. After 6 months, compared with the treatment with tyrosol, the effect of treatment was 2 times better. In contrast to TPOAbs in Graves' disease without treatment with vitamin D, where it did not differ depending on the level of 25 (OH) D, in the second group after 6 months of treatment there was a significant decrease in this indicator (p = 0.009). Compared to tyrosol treatment alone, there was a significant increase in TSH levels and a decrease in thyroid volume after 6 months. Data on the dependence of thyroid function on the level of 25 (OH) D were indicative. In each of the quartiles, the level of TSH after treatment with vitamin D was 4-5 times higher than in the group of patients treated only with tyrosol. Convincing data on the positive effect of vitamin D on autoimmune parameters, thyroid function and the need for its inclusion in the treatment of Graves' disease.

Keywords: Thyroid, Graves' Disease, Tyrosol, Vitamin D, TSH, TSH Receptor, Antibodies to Thyroxine Peroxidase, Free Thyroxine, Free Triiodothyronine, Thyroid Volume, Risk Factors

References

1. Bouillon R., et al. “Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions”. Endocrine Review4 (2019): 1109-1151.
2. Spiro A., et al. “Vitamin D: An overview of vitamin D status and intake in Europe”. Nutrition Bulletin4 (2014): 322-350.
3. Haussler MR., et al. “Vitamin D receptor (VDR)-mediated actions of 1α,25 (OH)2vitamin D3: genomic and non-genomic mechanisms”. Best Practice and Research: Clinical Endocrinology 4 (2011): 543-559.
4. Wang TJ., еt al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study”. Lancet 9736 (2010): 180-188.
5. Bouillon R. “Genetic and racial differences in the vitamin D endocrine system”. Endocrinology and Metabolism Clinics of North America 4 (2017): 1119-1135.
6. Dankers W., et al. “Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential”. Frontiers in Immunology 7 (2017): 697.
7. Zakharchenko TF., et al. “Peculiarities of innate and adaptive immunity in the pathogenesis of thyroid autoimmune diseases”. Immunocorrection (part 1) International Journal of Endocrinology (Ukraine)7 (2020): 564-576.
8. Kahaly GJ., et al. “European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism”. European Thyroid Journal4 (2018): 167-186.
9. Simsek Y., et al. “Effects of Vitamin D treatment on thyroid autoimmunity”. Journal of Research in Medical Sciences 21 (2016): 85.
10. Alhuzaim O., et al. “Effect of Vitamin D3 on Untreated Graves’ Disease with Vitamin D Deficiency”. Clinical Medicine Insights: Case Reports 7 (2014): 83-85.
11. Yasuda T., et al. “Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves’ disease”. Endocrine 42 (2012): 739-741.
12. Mangaraj S., et al. “Evaluation of Vitamin D Status and its Impact on Thyroid Related Parameters in New Onset Graves' Disease- A Cross-sectional Observational Study”. Indian Journal of Endocrinology and Metabolism 1 (2019): 35-39.
13. Brunn J., et al. “Volumetric analysis of thyroid lobes by real-time ultrasound (author’s transl)”. Dtsch Med Wochenschr41 (1981): 1338-1340.
14. Tsyb AF., et al. “Ul’trazvukovaia di¬agnostika zabolevanii shchitovidnoi zhelezy [Ultrasound diagnosis of thyroid diseases].” Moscow: Meditsina (1997): 332.
15. Sackett L., et al. “Evidence based medicine: what it is and what it isn't”. BMJ 312 (1996): 71.
16. Beaglehol R., et al. “Fundamentals of epidemiology”. Geneva: WHO (1994): 259.
17. Armitage P., et al. “Statistical Methods in Medical Research”. 4th Edition.
18. Pludowski P., et al. “Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency”. Endokrynologia Polska 4 (2014): 319-327.
19. Pludowski P., et al. “Vitamin D status in Central Europe”. International Journal of Endocrinology 2014 (2014): 589587.
20. Simsek Y., et al. “Effects of Vitamin D treatment on thyroid autoimmunity”. Journal of Research in Medical Sciences 21 (2016): 85.
21. Gallo D., et al. “Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review”. Journal of Endocrinological Investigation 4 (2020): 413-429.
22. Barragan M., et al. “Regulation of Dendritic Cell Function by Vitamin D”. Nutrients 9 (2015): 8127-8151.
23. Lee GJ., et al. “Differential effect of dietary vitamin D supplementation on natural killer cell activity in lean and obese mice”. Journal of Nutritional Biochemistry 55 (2018): 178-184.
24. Hoe E., et al. “Anti-Inflammatory Effects of Vitamin D on Human Immune Cells in the Context of Bacterial Infection”. Nutrients12 (2016): 806.
25. Bishop E., et al. “Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory”. JBMR Plus 1 (2020): e10405.5.

Citation

Citation: Victor Kravchenko., et al. “Relationship Between Vitamin D and Autoimmune Condition and Thyroid Function with Newly Onset Grave’s Disease”. Acta Scientific Women's Health 3.8 (2021): 65-73.

Copyright

Copyright: © 2021 Victor Kravchenko.,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.